Ariel Guo

As autoimmune T-cell engager development moves beyond first-generation approaches, the field is increasingly focused on identifying which immune-cell populations and biological pathways will deliver the safest, most selective, and most durable therapeutic responses.

In this interactive roundtable session, attendees will break into smaller discussion groups to evaluate the opportunities, challenges, and translational considerations associated with three of the most important target classes shaping the future of autoimmune T-cell engager development. Each group will discuss one of the following areas:

• Broad B-cell lineage markers, exploring the advantages and limitations of targeting widely expressed B-cell populations to achieve deep immune-cell depletion, rapid disease control, and scalable therapeutic applicability across multiple autoimmune indications
• Plasma cell reservoirs, discussing strategies to eliminate long-lived pathogenic plasma cells that may drive chronic disease persistence and relapse, while balancing infection risk, immune preservation, and long-term safety considerations
• Autoreactive antigen-specific B cells, evaluating emerging precision approaches designed to selectively target diseasedriving immune-cell populations while minimizing off-target immune depletion and preserving broader immune competence

• ATG-207 is a first-in-class immune tolerance-inducing biologic that integrates three key design elements: 1) CD3-mediated targeting, which localizes the molecule to T cells; 2) a conformationally dynamic masking mechanism, which reduces systemic TGF-B activity; and 3) TGFBRIII-biased signaling, which further enhances selectivity toward T cells
• ATG-207 leads to coordinated immune tolerance induction – promotion of Treg differentiation and controlled attenuation of pathogenic T cell activityATG-203 is a trispecific T-cell engager, leveraging Antengene proprietary OR-gated TriGagerTM platform, which enables a broad patient coverage across CD19+ pathogenic B cell population as well the plasmablast transition zone